Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
Myriad Genetics, MD Anderson Partner to Study Clinical Utility of MRD Assay
Under the five-year agreement, the partners will assess the clinical utility of Myriad's Precise MRD test in breast, gastrointestinal, genitourinary, and gynecological cancers.
Foresight Diagnostics, Stanford, Others File Motions to Dismiss Roche Suit
Foresight said Roche failed to bring its trade-secret causes of action within the three-year statute of limitations.
Lessons from the Phase III ZEST trial could inform ongoing and future trials as they seek to use ctDNA to prove efficacy of novel adjuvant treatments.
Personalis, Tempus Expand MRD Diagnostics Partnership to Include Biopharma
Tempus will now offer Personalis' NeXT Personal Dx minimal residual disease assay to pharmaceutical and biotech customers.
AstraZeneca to Use Tracer Biotechnologies Cancer Monitoring Tech for Clinical Trials
Tracer has developed a proprietary platform for tumor-informed circulating-tumor DNA detection using digital PCR.